Literature DB >> 21376641

Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells.

Ge Ma1, Ping-Ying Pan, Samuel Eisenstein, Celia M Divino, Clifford A Lowell, Toshiyuki Takai, Shu-Hsia Chen.   

Abstract

Myeloid-derived suppressor cells (MDSCs) bear characteristics of precursors for both M1 and M2 macrophages. The molecular mechanism underlying the differentiation into M1 and M2 macrophages and the relationship of this differentiation to antitumor responses remains largely undefined. Herein, we investigate the potential function of paired immunoglobulin-like receptor B (PIR-B), also known as leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3) in MDSC differentiation, and its role in tumor-induced immunity. Our studies indicated that MDSCs genetically ablated for PIR-B (Lilrb3(-/-)) underwent a specific transition to M1-like cells when entering the periphery from bone marrow, resulting in decreased suppressive function, regulatory T cell activation activity, primary tumor growth, and lung metastases. Activation of Toll-like receptor (TLR), signal transducers, and activators of transcription 1 (STAT1), and nuclear factor-kappa B (NF-κB) signaling in Lilrb3(-/-) MDSC promoted the acquisition of M1 phenotype. Inhibition of the PIR-B signaling pathway promoted MDSC differentiation into M1 macrophages.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376641      PMCID: PMC3064726          DOI: 10.1016/j.immuni.2011.02.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  46 in total

1.  Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.

Authors:  Naoki Umemura; Masanao Saio; Tatsuhiko Suwa; Yusuke Kitoh; Juncheng Bai; Kenichi Nonaka; Guan-Feng Ouyang; Makoto Okada; Margit Balazs; Roza Adany; Toshiyuki Shibata; Tsuyoshi Takami
Journal:  J Leukoc Biol       Date:  2008-02-19       Impact factor: 4.962

2.  STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

4.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

5.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  Exacerbated graft-versus-host disease in Pirb-/- mice.

Authors:  Akira Nakamura; Eiji Kobayashi; Toshiyuki Takai
Journal:  Nat Immunol       Date:  2004-05-16       Impact factor: 25.606

7.  Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1.

Authors:  M David; H E Chen; S Goelz; A C Larner; B G Neel
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

8.  Regulation of macrophage nitric oxide production by the protein tyrosine phosphatase Src homology 2 domain phosphotyrosine phosphatase 1 (SHP-1).

Authors:  Julie Blanchette; Issa Abu-Dayyeh; Kasra Hassani; Lorie Whitcombe; Martin Olivier
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

9.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Authors:  Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

Review 10.  Tumor versus tumor-associated macrophages: how hot is the link?

Authors:  C Guruvayoorappan
Journal:  Integr Cancer Ther       Date:  2008-06       Impact factor: 3.279

View more
  73 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 2.  Highlights of 10 years of immunology in Nature Reviews Immunology.

Authors:  Ruslan Medzhitov; Ethan M Shevach; Giorgio Trinchieri; Andrew L Mellor; David H Munn; Siamon Gordon; Peter Libby; Göran K Hansson; Ken Shortman; Chen Dong; Dmitry Gabrilovich; Leona Gabryšová; Ashleigh Howes; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

3.  Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.

Authors:  Sabrin H Albeituni; Chuanlin Ding; Min Liu; Xiaoling Hu; Fengling Luo; Goetz Kloecker; Michael Bousamra; Huang-ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

4.  Innate γδT17 cells play a protective role in DSS-induced colitis via recruitment of Gr-1+CD11b+ myeloid suppressor cells.

Authors:  Xuan Sun; Yihua Cai; Chris Fleming; Zan Tong; Zhenglong Wang; Chuanlin Ding; Minye Qu; Huang-Ge Zhang; Jian Suo; Jun Yan
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

5.  Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Authors:  Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2011-12-28       Impact factor: 3.969

Review 6.  LILRB receptor-mediated regulation of myeloid cell maturation and function.

Authors:  William van der Touw; Hui-Ming Chen; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Immunol Immunother       Date:  2017-06-21       Impact factor: 6.968

Review 7.  Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.

Authors:  Brent H Koehn; Bruce R Blazar
Journal:  J Leukoc Biol       Date:  2017-02-01       Impact factor: 4.962

8.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

9.  TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy.

Authors:  Padmini Jayaraman; Falguni Parikh; Jared M Newton; Aurelie Hanoteau; Charlotte Rivas; Rosemarie Krupar; Kimal Rajapakshe; Ravi Pathak; Kavin Kanthaswamy; Cassie MacLaren; Shixia Huang; Cristian Coarfa; Chad Spanos; Dean P Edwards; Robin Parihar; Andrew G Sikora
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

10.  Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

Authors:  Samuel Eisenstein; Brian A Coakley; Karen Briley-Saebo; Ge Ma; Hui-Ming Chen; Marcia Meseck; Stephen Ward; Celia Divino; Savio Woo; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.